Antithrombotics in heart failure: background to the WARCEF study

Pullicino, Patrick and Thompson, John L. P. (2003) Antithrombotics in heart failure: background to the WARCEF study. Seminars in Cerebrovascular Disease and Stroke, 3 . pp. 4-7. ISSN 1528-9931. (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided)

The full text of this publication is not available from this repository. (Contact us about this Publication)


Three controlled clinical studies in the early 1950s reported that warfarin reduced death and thromboembolism in patients with heart failure. Uncontrolled studies have suggested a reduction of stroke by warfarin in "cardiomyopathy" and many clinicians use warfarin for this purpose. The stroke rate in heart failure is low (about 2% per year) and this makes clinically useful risk reduction difficult and a prospective study costly. As for atrial fibrillation, there may be subgroups of heart failure patients with high-stroke risk who could benefit from warfarin and these need to be defined. Cognitive impairment is increasingly recognized as a complication of heart failure, and its risk factors need to be characterized. WARCEF (Warfarin vs. Aspirin in Reduced Cardiac Ejection Fraction) study reduces its sample size by combining death and stroke as the primary endpoint and by including patients with prior stroke.

Item Type: Article
Additional information: NOT IN FILE
Subjects: R Medicine > R Medicine (General)
Divisions: Faculties > Science Technology and Medical Studies > Kent Institute of Medicine and Health Sciences (KIMHS)
Depositing User: M.P. Stone
Date Deposited: 10 Sep 2008 13:44
Last Modified: 04 Jun 2014 09:28
Resource URI: (The current URI for this page, for reference purposes)
  • Depositors only (login required):


Downloads per month over past year